Serenity Disputes Protean Funds' Claims on SIVE, Cites Growth Projections

iconKuCoinFlash
Share
Share IconShare IconShare IconShare IconShare IconShare IconCopy
AI summary iconSummary

expand icon
Serenity challenges Protean Funds’ on-chain claims regarding SIVE’s CPO application status. The firm points out that Global Foundries has listed SIVE as a reference laser, and CPO has not yet achieved commercial scalability. Ecosystem growth projections indicate SIVE’s CPO TAM could increase from nearly zero to $91 billion by late 2026, reaching $141 billion by 2028. SIVE has partnered with Jabil in the pluggable market, with short-term sellers exposed to inflection point risks.

ME News reports that on June 5 (UTC+8), Serenity published a rebuttal to Protean Funds, a Swedish hedge fund, challenging its claim that SIVE’s CPO application is fabricated. Serenity pointed out that Global Foundries has recently listed SIVE as a reference laser, and since CPO technology has not yet been widely commercialized, current revenues cannot reflect future growth potential. From the second half of 2026 to 2028, the total addressable market (TAM) for CPOs related to SIVE is projected to surge from nearly zero to $91 billion, with an overall market size reaching $141 billion. Having already entered the pluggable market alongside players like Jabil, short sellers may be approaching a turning point. (Source: BlockBeats)

Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information. Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.